Evidence map›Paper›PMID 24166406›Full record

ReviewMolecular psychiatry2014

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.

E M P Poels, L S Kegeles, J T Kantrowitz, M Slifstein, D C Javitt, J A Lieberman, A Abi-Dargham, R R Girgis

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 6 pooled it
20.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 6 syntheses or guidelines pooled it, 209 citations in OpenAlex.

  1. Glutamatergic Modulation of Brain Function in Psychosis: A Systematic Review of Neuroimaging Studies.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Synaptic dysfunction and adaptation after NMDA receptor ablation in the mouse medial prefrontal cortex.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  14. Review
  15. Concerted elevations of cortical and striatal glutamate and GABA in antipsychotic-free individuals at clinical high-risk for psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

E M P Poels1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA.
L S Kegeles1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA.
J T Kantrowitz1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA.
M Slifstein1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA.
D C Javitt1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA.
J A Lieberman1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA.
A Abi-Dargham1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA [3] Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
R R Girgis1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA.
Columbia University · US

Funding

SUBCORTICAL DA FUNCTION IN SCHIZOPHRENIAP50MH066171 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI BEGG, MELISSA D · 2004 to 2008
$10.7M
CTSA: K12 COMPONENTKL2RR024157 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2006 to 2011
$8.9M
NCRR NIH HHS 2KL2RR024157-06NIMH NIH HHS P50 MH066171-01A1
6 · The paper itself

Abstract

Currently, all treatments for schizophrenia (SCZ) function primarily by blocking D(2)-type dopamine receptors. Given the limitations of these medications, substantial efforts have been made to identify alternative neurochemical targets for treatment development in SCZ. One such target is brain glutamate. The objective of this article is to review and synthesize the proton magnetic resonance spectroscopy ((1)H MRS) and positron emission tomography (PET)/single-photon emission computed tomography (SPECT) investigations that have examined glutamatergic indices in SCZ, including those of modulatory compounds such as glutathione (GSH) and glycine, as well as data from ketamine challenge studies. The reviewed (1)H MRS and PET/SPECT studies support the theory of hypofunction of the N-methyl-D-aspartate receptor (NMDAR) in SCZ, as well as the convergence between the dopamine and glutamate models of SCZ. We also review several advances in MRS and PET technologies that have opened the door for new opportunities to investigate the glutamate system in SCZ and discuss some ways in which these imaging tools can be used to facilitate a greater understanding of the glutamate system in SCZ and the successful and efficient development of new glutamate-based treatments for SCZ.

Indexed as

Drug DiscoveryAnimalsGlutamic AcidHumansNeuroimagingSchizophreniaGlutamic Acid

Identifiers

PMID24166406
OpenAlexW1997446269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.